Genetic variants associated with cisplatin-induced ototoxicity

被引:22
作者
Oldenburg, Jan [1 ,2 ]
Fossa, Sophie D. [1 ,2 ]
Ikdahl, Tone [3 ]
机构
[1] Univ Oslo, Rikshosp, Norwegian Radium Hosp, Dept Clin Canc Res, N-0310 Oslo, Norway
[2] Univ Oslo, Norwegian Radium Hosp, Fac Div, N-0316 Oslo, Norway
[3] Ullevaal Univ Hosp, Ulleval Canc Ctr, Oslo, Norway
关键词
audiometric; chemotherapy; cisplatin; glutathione; GST; GSTM1; GSTP1; hearing impairment; hearing loss; ototoxicity; pharmacogenetics; polymorphism; tinnitus;
D O I
10.2217/14622416.9.10.1521
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cisplatin induces ototoxicity with a huge interindividual variation, which is at least partly based on genetic differences between the affected individuals. Identification of genetic variants that could predict the severity of ototoxicity is an important step towards a more individualized cisplatin treatment. Nevertheless, so far, only a few studies have assessed this issue. This review will address the prevalence of cisplatin-induced ototoxicity, its pathophysiology, quantification and associations with genetic variants. The recent progress in both phenotyping and genotyping is discussed.
引用
收藏
页码:1521 / 1530
页数:10
相关论文
共 49 条
[31]   Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose [J].
Li, Y ;
Womer, RB ;
Silber, JH .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) :2445-2451
[32]   Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors - A children's Oncology Group study [J].
Marina, N ;
Chang, KW ;
Malogolowkin, M ;
London, WB ;
Frazier, AL ;
Womer, RB ;
Rescorla, F ;
Billmire, DF ;
Davis, MM ;
Perlman, EJ ;
Giller, R ;
Lauer, SJ ;
Olson, TA .
CANCER, 2005, 104 (04) :841-847
[33]   Curing metastatic cancer:: Lessons from testicular germ-cell tumours [J].
Masters, JRW ;
Köberle, B .
NATURE REVIEWS CANCER, 2003, 3 (07) :517-525
[34]   Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and-M1, a retrospective cross sectional study [J].
Oldenburg, Jan ;
Kraggerud, Sigrid M. ;
Brydoy, Marianne ;
Cvancarova, Milada ;
Lothe, Ragnhild A. ;
Fossa, Sophie D. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
[35]   Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors [J].
Oldenburg, Jan ;
Kraggerud, Sigrid M. ;
Cvancarova, Milada ;
Lothe, Ragnhild A. ;
Fossa, Sophie D. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) :708-714
[36]   Scale for chemotherapy-induced long-term neurotoxicity (SCIN):: Psychometrics, validation, and findings in a large sample of testicular cancer survivors [J].
Oldenburg, Jan ;
Fossa, Sophie D. ;
Dahl, Alv A. .
QUALITY OF LIFE RESEARCH, 2006, 15 (05) :791-800
[37]   LONG-TERM EFFECTS OF CHEMOTHERAPY IN PATIENTS WITH TESTICULAR CANCER [J].
OSANTO, S ;
BUKMAN, A ;
VANHOEK, F ;
STERK, PJ ;
DELAAT, JAPM ;
HERMANS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :574-579
[38]  
Peters U, 2003, ANTICANCER RES, V23, P1249
[39]   Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin [J].
Peters, U ;
Preisler-Adams, S ;
Hebeisen, A ;
Hahn, M ;
Seifert, E ;
Lanvers, C ;
Heinecke, A ;
Horst, J ;
Jürgens, H ;
Lamprecht-Dinnesen, A .
ANTI-CANCER DRUGS, 2000, 11 (08) :639-643
[40]   Relationship between cisplatin administration and the development of ototoxicity [J].
Rademaker-Lakhai, JM ;
Crul, M ;
Zuur, L ;
Baas, P ;
Beijnen, JH ;
Simis, YJW ;
van Zandwijk, N ;
Schellens, JHM .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :918-924